Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07330674 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses
A Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration, sponsored by Aptabio Therapeutics.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 68
- Enrollment target
- 1
- Study location
NCT07330674: Recruiting Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration, sponsored by Aptabio Therapeutics.
NCT07330674 is a Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration that is actively recruiting participants, run by Aptabio Therapeutics. The registered enrollment target is 68 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07330674, a Phase 1 study of Age Related Macular Degeneration (ARMD) and AMD - Age-Related Macular Degeneration, is actively recruiting participants, sponsored by Aptabio Therapeutics.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 68 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
Primary Outcome
To investigate the safety and tolerability of single ascending dose of ABF-101orally administered in healthy participants (Part A and B) and in AMD (Part C)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG ABF-101
Study Locations (1)
Texas
- Dallas Clinical Research Unit - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 68 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-12 |
| Phase | Phase 1 |
What NCT07330674 shows while recruiting
NCT07330674 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 68 participants, a relatively small participant target, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% higher).
The record links to 2 conditions, with Age Related Macular Degeneration (ARMD) appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07330674 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT07330674 about?
NCT07330674 is a clinical study titled "A Phase 1 Study of ABF-101 in Single- and Multiple-Ascending Doses". This is a Phase 1 study to evaluate the safety, tolerability, PK, and PD of ABF-101 in healthy participants and participants with age-related macular degeneration (AMD).
What is the current status of trial NCT07330674?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 68 participants. The study started on 2026-02. Estimated completion is 2027-12.
What conditions does trial NCT07330674 study?
This clinical trial studies the following conditions: Age Related Macular Degeneration (ARMD), AMD - Age-Related Macular Degeneration.
What interventions are being tested in trial NCT07330674?
The interventions under investigation include: Placebo (DRUG), ABF-101 (DRUG).
Who is sponsoring clinical trial NCT07330674?
This trial is sponsored by Aptabio Therapeutics, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07330674 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Age Related Macular Degeneration (ARMD)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07330674's enrollment target sits among peer trials
68 777th of 2000 higher than 1,219 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02044497 · 68 participants · Phase 4
Population Pharmacokinetics and Pharmacogenomics of Oral Oxycodone in Pediatric Surgical Patients
- NCT03779854 · 68 participants · Phase 2
Naive T Cell Depletion for Preventing Chronic Graft-versus-Host Disease in Children and Young Adults With Blood Cancers Undergoing Donor Stem Cell Transplant
- NCT03821246 · 68 participants · Phase 2
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
- NCT04115514 · 68 participants · Phase 2
Treatment of ARDS With Instilled T3
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia